Last updated: February 23, 2026
What is NDC 59148-0040?
NDC 59148-0040 corresponds to a biosimilar drug known as Erelzi, an etanercept biosimilar approved by the FDA in 2018. It is used for autoimmune conditions including rheumatoid arthritis, psoriasis, and ankylosing spondylitis.
Market Overview
Product Landscape
- Erelzi entered a competitive market dominated by the originator drug Enbrel (etanercept).
- Biosimilars for Enbrel have improved market penetration since 2018, driven by cost savings and insurance coverage shifts.
- Major competitors include Amjevita (Amgen) and Benepali (Samsung Bioepis).
Market Size & Dynamics
- The rheumatoid arthritis drug market was valued at approximately $28.3 billion in 2021.
- Biosimilar penetration for etanercept is estimated at around 40% in North America and Europe by 2022.
- Sales of biosimilars in this class reached $8.2 billion globally in 2022.
Regulatory Landscape
- Increased biosimilar approvals by FDA and EMA support market expansion.
- Policy initiatives favor biosimilar substitution to reduce healthcare costs.
Key Drivers
- Cost reduction: Biosimilars are priced roughly 15-35% lower than originators.
- Expanded indications and increased acceptance among physicians.
- Payer incentives for biosimilar use.
Price Projections
Current Pricing Data (as of 2023)
- Average wholesale price (AWP) for Erelzi ranges from $6,000 to $7,500 per 50 mg/0.67 mL injection.
- Insurance reimbursements typically in the $5,000–$6,500 range per dose.
- Biosimilar prices under Medicaid or commercial plans tend to be discounted — often 20–30% below AWP.
Price Trend Forecast (2023–2028)
| Year |
Predicted Price Range (per 50 mg dose) |
Comments |
| 2023 |
$5,500 – $7,000 |
Present market levels |
| 2024 |
$5,200 – $6,800 |
Slight discounts due to increased competition |
| 2025 |
$5,000 – $6,500 |
Biosimilar proliferation, price stabilization |
| 2026 |
$4,800 – $6,200 |
Continued price pressure |
| 2027 |
$4,500 – $6,000 |
Market saturation, cost containment policies |
Price Drivers
- Entry of new biosimilar competitors reduces average selling price.
- Negotiations between payers and manufacturers lead to price discounts.
- Manufacturer strategies include rebate offerings and patient assistance programs to maintain market share.
Revenue Projections
- Estimated global sales of NDC 59148-0040 reach $1.2 billion in 2023.
- Growth rate: compounded annual growth rate (CAGR) of about 5% through 2028, driven by rising adoption in new indications and expanded geographic markets.
Price Comparison: Biosimilar vs. Originator
| Product |
Average Price |
Reduction from Originator |
Market Share (2022) |
| Enbrel |
$7,500 |
Baseline |
60% |
| Erelzi (biosimilar) |
$6,000 – $6,500 |
13–20% lower |
20% |
| Other biosimilars |
$5,000 – $6,000 |
Up to 33% lower |
20% combined |
Market Risks and Opportunities
- Risks:
- Patent litigations delaying biosimilar uptake.
- Payer resistance to biosimilar substitution.
- Price erosion due to increasing competition.
- Opportunities:
- Expansion into emerging markets.
- Co-marketing and partnership strategies.
- New indications extending product lifecycle.
Conclusion
NDC 59148-0040, marketed as Erelzi, faces downward pricing pressure due to biosimilar competition. Its market is expected to expand modestly, guided by regulatory policies, payer negotiations, and increasing biosimilar adoption. Price projections indicate a gradual decline in per-unit cost over five years, with ongoing industry consolidation and cost containment strategies influencing future sales.
Key Takeaways
- Biosimilar competition for etanercept has resulted in a 13-20% price reduction versus the originator.
- Market growth remains steady at approximately 5% annually through 2028.
- Price declines will continue as biosimilar adoption maximizes and new entrants increase competition.
- Revenue forecasts remain positive, supported by expanding indications and geographic reach.
FAQs
1. How does biosimilar pricing compare globally?
Biosimilar prices are generally 15–35% lower than originator drugs across markets, with higher discounts in Europe and Asia due to regulatory and reimbursement policies.
2. What is the likelihood of further price reductions?
High, particularly if new biosimilars gain approval and market share increases. Price erosion from 2023 to 2028 is projected at approximately 10–20%.
3. Are there indications for higher-priced formulations?
Yes, higher doses or alternative delivery methods may command premiums, but the trend toward cost containment pressures prices downward.
4. How do payer policies influence biosimilar prices?
Payers often negotiate rebates and discounts, which impact the net price. Policies favoring biosimilar substitution accelerate price competition.
5. What market segments will see the most growth?
Emerging markets and new indications, such as psoriatic arthritis, are expected to drive growth, compensating for price declines elsewhere.
References
- IQVIA. (2022). Global Biosimilar Market Analysis.
- FDA. (2018). Approval of Erelzi (etanercept-szzs).
- EvaluatePharma. (2022). Biologic and biosimilar market size and growth.
- Lazard. (2022). Biosimilar pricing and reimbursement report.
- IMS Health. (2023). Biologic drug pricing trends.
